Progyny Reports Record Revenue and EBITDA for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy PGNY?
Source: seekingalpha
- Record Financial Performance: Progyny achieved $1.29 billion in revenue and $222 million in adjusted EBITDA for 2025, exceeding the midpoint of original guidance by nearly $90 million and $28 million respectively, showcasing the company's robust market performance and profitability.
- Strong Cash Flow Growth: The operating cash flow reached a record $210 million in 2025, reflecting a 17% increase over 2024, which provides strong support for future investments and shareholder returns, further solidifying the company's financial health.
- Near 100% Client Retention: Progyny reported nearly 100% client retention among large employers, with 30% of clients expanding benefits for 2026, indicating sustained competitiveness and high customer satisfaction in the market.
- New Product Strategic Launch: The introduction of Progyny Select targets the needs of 50 million smaller employers, expected to contribute new revenue streams in 2027, marking a strategic shift in the company's focus and further expanding its market share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PGNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PGNY
Wall Street analysts forecast PGNY stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 23.720
Low
26.00
Averages
29.75
High
34.00
Current: 23.720
Low
26.00
Averages
29.75
High
34.00
About PGNY
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Progyny CEO and CFO to Participate in BofA Health Conference
- Executive Participation: Progyny's CEO Pete Anevski and CFO Mark Livingston will participate in the BofA Securities 2026 Health Care Conference on May 12, 2026, highlighting the company's leadership in women's health and family building solutions.
- Live Audiocast Available: The conference will take place at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time, with a live audiocast and replay accessible on Progyny's website, ensuring timely information for investors and stakeholders.
- Industry Recognition: Progyny has been recognized as a TIME100 Most Influential Company, CNBC Disruptor 50, and Modern Healthcare's Best Places to Work, underscoring its innovation and market impact in the women's health sector, further solidifying its leadership position in the industry.
- Comprehensive Solution Benefits: Progyny's benefits solutions empower patients with personalized support, education, and digital tools, driving optimal clinical outcomes while reducing healthcare costs, demonstrating strategic significance in enhancing patient experience and optimizing employer benefits.
See More
Progyny CEO and CFO to Participate in BofA Health Conference
- Executive Participation: Progyny's CEO Pete Anevski and CFO Mark Livingston will participate in the BofA Securities 2026 Health Care Conference on May 12, 2026, highlighting the company's leadership in women's health and family building solutions.
- Live Audiocast: The event is scheduled for 11:20 A.M. Pacific Time (2:20 P.M. Eastern Time), with a live audiocast and replay available on Progyny's website, ensuring timely access to information for investors and stakeholders.
- Industry Recognition: Progyny has been recognized as a TIME100 Most Influential Company, CNBC Disruptor 50, and Modern Healthcare's Best Places to Work, showcasing its innovation and growth in the women's health sector and further solidifying its market position.
- Comprehensive Solution Benefits: Progyny's benefits solutions empower patients with personalized support, education, and digital tools, driving optimal clinical outcomes while reducing healthcare costs, demonstrating its competitive advantage in the industry.
See More
Progyny Reports Q1 2026 Financial Results and Outlook
- Stable Financial Performance: Progyny reported net revenues of $328.5 million in Q1 2026, relatively stable compared to $324.04 million in the same quarter last year, with fertility benefits contributing $209.4 million and pharmacy benefits $119.1 million, indicating sustained demand in women's health solutions.
- Significant Profit Growth: The company achieved gross profits of $83.07 million with a gross margin of 25.3%, a notable increase from $75.79 million in the previous year, reflecting successful cost control and service optimization strategies.
- Optimistic Future Outlook: Progyny anticipates revenue growth of 2.7%-6.6% for Q2 2026, projecting revenues between $342 million and $355 million, with adjusted EBITDA estimated at $58 million to $62 million, showcasing positive expectations for market demand.
- Stock Buyback Initiative: In Q1 2026, Progyny repurchased approximately 5.5 million shares of its common stock, demonstrating confidence in its stock value while also creating additional value for shareholders.
See More
Progyny Reports Record Q1 2026 Earnings Exceeding Expectations
- Significant Revenue Growth: Progyny reported Q1 2026 revenue of $328.5 million, reflecting over 12% growth year-over-year, exceeding expectations and demonstrating strong market performance and sustained client demand.
- Enhanced Profitability: The company projects adjusted EBITDA between $232 million and $244 million, with net income expected between $103.7 million and $112.3 million, indicating a positive outlook for future profitability and bolstering investor confidence.
- Share Repurchase Program: Progyny completed a $200 million share repurchase program, buying back over 8.8 million shares, showcasing management's confidence in the company's value, with plans to decide on a new buyback program by the end of May, potentially enhancing shareholder returns.
- Stable Cash Flow: The company generated approximately $46 million in operating cash flow for the quarter, totaling over $200 million on a trailing 12-month basis, maintaining this level for five consecutive quarters, ensuring financial flexibility for future investments and operations.
See More
Progynypress Releases 2026 Financial Outlook with Strong Q1 Results
- Q1 Performance Exceeds Expectations: Progynypress reported a Q1 non-GAAP EPS of $0.50, beating estimates by $0.06, with revenue of $328.5 million reflecting a 1.4% year-over-year increase, surpassing expectations by $1.99 million, indicating robust performance in the healthcare sector.
- 2026 Full-Year Outlook: The company projects 2026 revenue between $1.365 billion and $1.405 billion, reflecting growth of 5.9% to 9.0%; excluding $48.5 million from a large client in 2025, revenue growth is expected to be 10.1% to 13.3%, showcasing strong future growth potential.
- Net Income and Adjusted EBITDA Projections: Net income is projected to range from $103.7 million to $112.3 million, translating to $1.23 to $1.34 per diluted share, while adjusted EBITDA is expected to be between $232.0 million and $244.0 million, indicating ongoing enhancement in profitability.
- Q2 Outlook: For Q2 2026, revenue is projected at $342.0 million to $355.0 million, reflecting growth of 2.7% to 6.6%; excluding $17.2 million from a large client in 2025, growth is expected to be 8.3% to 12.4%, demonstrating the company's sustained competitiveness in the market.
See More
Progyny to Report Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Progyny will report its financial results for the quarter ending March 31, 2026, after market close on May 7, 2026, indicating the company's ongoing growth in women's health and family building solutions.
- Conference Call Details: The company will host a conference call at 4:45 p.m. Eastern Time, with participants able to access it by dialing 1.866.825.7331 (U.S.) or 1.973.413.6106 (international) using passcode 265484, ensuring transparent communication of financial results.
- Audio Replay Service: An audio replay of the call will be available until May 14, 2026, allowing participants to access it by dialing 1.800.332.6854 (U.S.) or 1.973.528.0005 (international), enhancing the accessibility of important information.
- Company Background: Progyny is a global leader in women's health and family building solutions, recognized with honors such as TIME100 and CNBC Disruptor 50, showcasing its influence and growth potential in the industry.
See More
Progyny CEO and CFO to Participate in BofA Health Conference
- Executive Participation: Progyny's CEO Pete Anevski and CFO Mark Livingston will participate in the BofA Securities 2026 Health Care Conference on May 12, 2026, highlighting the company's leadership in women's health and family building solutions.
- Live Audiocast Available: The conference will take place at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time, with a live audiocast and replay accessible on Progyny's website, ensuring timely information for investors and stakeholders.
- Industry Recognition: Progyny has been recognized as a TIME100 Most Influential Company, CNBC Disruptor 50, and Modern Healthcare's Best Places to Work, underscoring its innovation and market impact in the women's health sector, further solidifying its leadership position in the industry.
- Comprehensive Solution Benefits: Progyny's benefits solutions empower patients with personalized support, education, and digital tools, driving optimal clinical outcomes while reducing healthcare costs, demonstrating strategic significance in enhancing patient experience and optimizing employer benefits.
See More
Progyny CEO and CFO to Participate in BofA Health Conference
- Executive Participation: Progyny's CEO Pete Anevski and CFO Mark Livingston will participate in the BofA Securities 2026 Health Care Conference on May 12, 2026, highlighting the company's leadership in women's health and family building solutions.
- Live Audiocast: The event is scheduled for 11:20 A.M. Pacific Time (2:20 P.M. Eastern Time), with a live audiocast and replay available on Progyny's website, ensuring timely access to information for investors and stakeholders.
- Industry Recognition: Progyny has been recognized as a TIME100 Most Influential Company, CNBC Disruptor 50, and Modern Healthcare's Best Places to Work, showcasing its innovation and growth in the women's health sector and further solidifying its market position.
- Comprehensive Solution Benefits: Progyny's benefits solutions empower patients with personalized support, education, and digital tools, driving optimal clinical outcomes while reducing healthcare costs, demonstrating its competitive advantage in the industry.
See More
Progyny Reports Q1 2026 Financial Results and Outlook
- Stable Financial Performance: Progyny reported net revenues of $328.5 million in Q1 2026, relatively stable compared to $324.04 million in the same quarter last year, with fertility benefits contributing $209.4 million and pharmacy benefits $119.1 million, indicating sustained demand in women's health solutions.
- Significant Profit Growth: The company achieved gross profits of $83.07 million with a gross margin of 25.3%, a notable increase from $75.79 million in the previous year, reflecting successful cost control and service optimization strategies.
- Optimistic Future Outlook: Progyny anticipates revenue growth of 2.7%-6.6% for Q2 2026, projecting revenues between $342 million and $355 million, with adjusted EBITDA estimated at $58 million to $62 million, showcasing positive expectations for market demand.
- Stock Buyback Initiative: In Q1 2026, Progyny repurchased approximately 5.5 million shares of its common stock, demonstrating confidence in its stock value while also creating additional value for shareholders.
See More
Progyny Reports Record Q1 2026 Earnings Exceeding Expectations
- Significant Revenue Growth: Progyny reported Q1 2026 revenue of $328.5 million, reflecting over 12% growth year-over-year, exceeding expectations and demonstrating strong market performance and sustained client demand.
- Enhanced Profitability: The company projects adjusted EBITDA between $232 million and $244 million, with net income expected between $103.7 million and $112.3 million, indicating a positive outlook for future profitability and bolstering investor confidence.
- Share Repurchase Program: Progyny completed a $200 million share repurchase program, buying back over 8.8 million shares, showcasing management's confidence in the company's value, with plans to decide on a new buyback program by the end of May, potentially enhancing shareholder returns.
- Stable Cash Flow: The company generated approximately $46 million in operating cash flow for the quarter, totaling over $200 million on a trailing 12-month basis, maintaining this level for five consecutive quarters, ensuring financial flexibility for future investments and operations.
See More
Progynypress Releases 2026 Financial Outlook with Strong Q1 Results
- Q1 Performance Exceeds Expectations: Progynypress reported a Q1 non-GAAP EPS of $0.50, beating estimates by $0.06, with revenue of $328.5 million reflecting a 1.4% year-over-year increase, surpassing expectations by $1.99 million, indicating robust performance in the healthcare sector.
- 2026 Full-Year Outlook: The company projects 2026 revenue between $1.365 billion and $1.405 billion, reflecting growth of 5.9% to 9.0%; excluding $48.5 million from a large client in 2025, revenue growth is expected to be 10.1% to 13.3%, showcasing strong future growth potential.
- Net Income and Adjusted EBITDA Projections: Net income is projected to range from $103.7 million to $112.3 million, translating to $1.23 to $1.34 per diluted share, while adjusted EBITDA is expected to be between $232.0 million and $244.0 million, indicating ongoing enhancement in profitability.
- Q2 Outlook: For Q2 2026, revenue is projected at $342.0 million to $355.0 million, reflecting growth of 2.7% to 6.6%; excluding $17.2 million from a large client in 2025, growth is expected to be 8.3% to 12.4%, demonstrating the company's sustained competitiveness in the market.
See More
Progyny to Report Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Progyny will report its financial results for the quarter ending March 31, 2026, after market close on May 7, 2026, indicating the company's ongoing growth in women's health and family building solutions.
- Conference Call Details: The company will host a conference call at 4:45 p.m. Eastern Time, with participants able to access it by dialing 1.866.825.7331 (U.S.) or 1.973.413.6106 (international) using passcode 265484, ensuring transparent communication of financial results.
- Audio Replay Service: An audio replay of the call will be available until May 14, 2026, allowing participants to access it by dialing 1.800.332.6854 (U.S.) or 1.973.528.0005 (international), enhancing the accessibility of important information.
- Company Background: Progyny is a global leader in women's health and family building solutions, recognized with honors such as TIME100 and CNBC Disruptor 50, showcasing its influence and growth potential in the industry.
See More
